APOLLO Study | Int'l Myeloma Foundation
Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM - Medical Conferences
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy
Multiple Myeloma Support + Trials
The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management | Value-Based Cancer Care
ASH 2020: Subcutaneous DARZALEX® Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma – OncoPrescribe
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Relapsed: D + PD Treatment | DARZALEX® IV (daratumumab)
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement - Justin R Arnall, Saad Z Usmani, Hawawu
Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective treatment option for MM - BJH
Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma - The ASCO Post
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ...
Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma
FDA
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment | Leukemia
Daratumumab - wikidoc
